Health and Healthcare

Short Selling Up in Drug & Medical Stocks

Some sectors showed mixed results in the short selling, but the Big Pharma and medical instruments and related companies saw an increased activity in short selling in May versus April.  Below is the actual posting from April to May:

STOCK (Ticker)                        MAY07    APR07    Change
Pfizer (PFE)                               52.12M    50.28M    3.6%
Merck (MRK)                             22.55M    18.68M    20.6%
Johnson & Johnson (JNJ)    16.16M    14.47M    11.7%
Abbott Labs (ABT)                   16.39M    14.90M    10%
Wyeth (WYE)                            10.37M    9.61M       7.9%
Eli Lilly (LLY)                            14.07M    10.95M    28.5%
Bristol-Myers (BMY)                23.85M    18.75M    27.2%
Schering-Plough (SGP)        15.27M    14.09M      8.3%
Medtronic (MDT)                      15.19M    13.81M     9.9%
Boston Scientific (BSX)          24.06M    21.65M     11.1%
St. Jude MEdical (STJ)             7.13M    5.85M        21.8%
Quest Diagnost. (DGX)          17.54M    16.57M     11.1%

lower short interest…..

GlaxoSmithkline (GSK)            5.15M    4.66M    -11%
Genentech (DNA)                      8.16M    8.76M    -6.8%
Zimmer Holdings (ZMH)          4.13M    5.00M    -17%
Labcorp (LH)                              3.21M    3.34M    -3.9%

Jon C. Ogg
May 22, 2007

Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.

Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE

Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.